Downey, William
June 2014
Contract Pharma;Jun2014, Vol. 16 Issue 5, p60
Trade Publication
The article discusses the growth of the demand for biopharmaceutical contract manufacturing services. Topics include the increase in sales observed by contract manufacturing organization (CMO) leaders in 2013, the positive impact of the increased investment in biopharma on CMO, and the increasing interests of clients seen by the industry for antibody drug conjugates (ADCs) and pegylated biopharmaceuticals.


Related Articles

  • Wondering What You Missed in BioWorld Insight?  // BioWorld Today;8/8/2012, Vol. 23 Issue 153, p7 

    The article provides updates in the biopharmaceutical industry in the U.S. including the field of research surrounding antibody-drug conjugates (ADCs), Amarin Corp. PLC's triglyceride-lowering drug Vascepa, and a projected 1 .6 million new cancer cases and 577,190 deaths from cancer.

  • Astrazeneca Paying up to $440M For Payload Tech Firm Spirogen. Moran, Nuala // BioWorld International;10/16/2013, Vol. 18 Issue 42, p1 

    The article reports that the Astrazeneca in London, England will be paying off for $200 million in cash for the acquisition of the payload technology company Spirogen PLC. It states that concurrently, Astrazeneca's Medimmune antibody unit is creating a $20 million investment in the existing...

  • High Interest in High Potency. Roth, Gil // Contract Pharma;Sep2011, Vol. 13 Issue 7, p50 

    The article focuses on the expansion of the contract manufacturing organization (CMO) market. It cites the developments in oncological therapeutics, antibody drug conjugates (ADCs) and liposomal formulations as key client needs. It also highlights the highlights the statement of doctor Laura L....

  • Piramal Healthcare.  // Contract Pharma;2013 Corporate Capabilities & Contract Services Directory, p174 

    The article profiles Piramal Healthcare Ltd., the Contract Development and Manufacturing (CDMO) arm of Piramal Enterprises Ltd. It states that the firm is a CMO which provides support in pharmaceutical drug products ad services. It mentions that the company accepts customer partnerships in...

  • Conjugate Reverb: Abbott Pays $25M to Broaden SeaGen Deal. Osborne, Randy // BioWorld Today;10/24/2012, Vol. 23 Issue 207, p1 

    This article reports on the October 2012 decision of pharmaceutical firm Abbott to pay 25 million U.S. dollars for the expansion of a 2011 deal with Seattle Genetics Inc. over the latter company's antibody-drug conjugate (ADC) Adcetris. The expansion will allow Abbott to use the ADC technology...

  • Synthon to Debut New Focus With HER2-ADC Data at AACR. Moran, Nuala // BioWorld International;4/3/2013, Vol. 18 Issue 14, p2 

    The article reports on Synthon Biopharmaceuticals' planned session at the 2013 American Association for Cancer Research (AACR) meeting to discuss details of its primary antibody-drug conjugate (ADC) product. A comparison of AACR's product with the first two ADCs in the market will be the center...

  • OTHER NEWS TO NOTE.  // BioWorld Today;12/13/2013, Vol. 24 Issue 239, p10 

    The article offers news briefs in the biopharmaceutics industry in 2013. Ico Therapeutics Inc.'s s oral amphotericin B is entering in vitro testing with study partners in Montreal to explore the role of the formulation in targeting latent HIV reservoirs. Therapeutics Inc. is set to design...

  • ANTITOPE AND SYNTHON ANNOUNCE COLLABORATION.  // Biotech Business;Aug2014, Vol. 27 Issue 8, p4 

    The article reports the collaboration of Antitope Ltd., a provider of proprietary technologies to develop biopharmaceuticals, with Synthon Biopharmaceuticals BV. Topics discussed include collaboration's aim to provide potential immunogenicity of candidate antibodies for antibody drug conjugates...

  • Antibody Drug Conjugates: A Marriage of Biologics and Small Molecules. Van Arnum, Patricia // Pharmaceutical Technology;Jun2008, Vol. 32 Issue 6, p54 

    The article focuses on the importance of antibody drug conjugates (ADCs) as part of anticancer drug development in the U.S. It cites that ADCs, or monoclonal antibodies linked to a cytotoxic small molecule, provide a niche opportunity for biopharmaceutical companies and contract manufacturers....


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics